Cutaneous T-cell lymphoma: 2016 Update on diagnosis, risk-stratification, and management

被引:0
|
作者
Wilcox, Ryan A. [1 ]
机构
[1] Univ Michigan, Div Hematol Oncol, Ctr Canc, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
HISTONE DEACETYLASE INHIBITOR; PHASE-II TRIAL; NF-KAPPA-B; MYCOSIS FUNGOIDES/SEZARY-SYNDROME; PEGYLATED LIPOSOMAL DOXORUBICIN; PERIPHERAL-BLOOD LYMPHOCYTES; LOW-DOSE METHOTREXATE; ANTI-CD52; MONOCLONAL-ANTIBODY; PREDICTS SUPERIOR SURVIVAL; GAMMA-GENE REARRANGEMENT;
D O I
10.1002/ajh.24233
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disease overview: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sezary Syndrome (SS). Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data. Risk-adapted therapy: TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a "risk-adapted," multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin-directed therapies is preferred, as both disease-specific and overall survival for these patients is favorable. In contrast, patients with advanced-stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic-response modifiers or histone deacetylase inhibitors before escalating therapy to include systemic, single-agent chemotherapy. In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:152 / 165
页数:14
相关论文
共 50 条